Morningstar Investment Services LLC Has $4.33 Million Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Morningstar Investment Services LLC increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 109.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 44,602 shares of the biotechnology company’s stock after acquiring an additional 23,288 shares during the period. Morningstar Investment Services LLC’s holdings in BioMarin Pharmaceutical were worth $4,332,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. KB Financial Partners LLC raised its stake in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Lindbrook Capital LLC increased its holdings in BioMarin Pharmaceutical by 259.8% during the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 278 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its position in BioMarin Pharmaceutical by 135.3% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 249 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in BioMarin Pharmaceutical in the fourth quarter worth $43,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of BioMarin Pharmaceutical by 33.3% during the fourth quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 144 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

BMRN has been the subject of a number of research analyst reports. Morgan Stanley cut their price target on BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating for the company in a report on Friday, April 26th. Robert W. Baird downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $104.00 to $72.00 in a research note on Friday, May 17th. Wells Fargo & Company upped their target price on shares of BioMarin Pharmaceutical from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Royal Bank of Canada reissued a “sector perform” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Finally, Canaccord Genuity Group dropped their price objective on shares of BioMarin Pharmaceutical from $91.00 to $89.00 and set a “hold” rating for the company in a research report on Friday, April 26th. Nine research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $106.11.

Get Our Latest Report on BioMarin Pharmaceutical

Insider Transactions at BioMarin Pharmaceutical

In related news, EVP George Eric Davis sold 1,850 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $85.01, for a total value of $157,268.50. Following the sale, the executive vice president now directly owns 56,157 shares of the company’s stock, valued at approximately $4,773,906.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,850 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total transaction of $157,268.50. Following the completion of the transaction, the executive vice president now owns 56,157 shares in the company, valued at approximately $4,773,906.57. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brian Mueller sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $75.19, for a total value of $375,950.00. Following the completion of the sale, the chief financial officer now owns 72,159 shares in the company, valued at $5,425,635.21. The disclosure for this sale can be found here. Insiders sold 114,588 shares of company stock valued at $9,413,633 over the last quarter. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Down 0.2 %

NASDAQ:BMRN opened at $80.69 on Friday. BioMarin Pharmaceutical Inc. has a 1 year low of $73.68 and a 1 year high of $99.56. The stock has a 50-day moving average price of $82.85 and a two-hundred day moving average price of $88.09. The stock has a market cap of $15.32 billion, a price-to-earnings ratio of 75.41, a PEG ratio of 1.15 and a beta of 0.31. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Free Report) last posted its earnings results on Wednesday, April 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.12. The business had revenue of $648.83 million during the quarter, compared to analysts’ expectations of $649.75 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. As a group, equities analysts expect that BioMarin Pharmaceutical Inc. will post 1.99 earnings per share for the current year.

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.